Molecule
Fezolinetant is a neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. It is available as tablets for oral use. MedsAcross supplies Fezolinetant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VEOZAH ® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Source: US FDA prescribing information
VEOZAH is a neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center. Fezolinetant has high affinity for the NK3 receptor (Ki value of 19.9 to 22.1 nmol/L), which is more than 450-fold higher than binding affinity to NK1 or NK2 receptors.
Source: US FDA prescribing information
One 45 mg tablet orally once daily with or without food. Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury before beginning VEOZAH. While using VEOZAH, perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy or when signs or symptoms suggest liver injury.
Source: US FDA prescribing information
VEOZAH is contraindicated in women with any of the following conditions: • Known cirrhosis. • Severe renal impairment or end-stage renal disease. • Concomitant use with CYP1A2 inhibitors. • Known cirrhosis. • Severe renal impairment or end-stage renal disease. • Concomitant use with CYP1A2 inhibitors
Source: US FDA prescribing information
Boxed warning (risks of hepatotoxicity): Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting. • Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory. Hepatotoxicity: Cases of hepatotoxicity and jaundice have been reported in the postmarketing setting. Perform hepatic laboratory tests prior to initiation of VEOZAH to evaluate for hepatic function and injury. Perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy.
Source: US FDA prescribing information
The following serious adverse reactions are discussed elsewhere in the labeling: • Hepatic Transaminase Elevation and Hepatotoxicity. The most common adverse reactions with VEOZAH [at least 2% in VEOZAH 45 mg and greater than placebo] are: abdominal pain, diarrhea, insomnia, back pain, hot flush, and hepatic transaminase elevation.
Source: US FDA prescribing information
Effect of Other Drugs on VEOZAH CYP1A2 Inhibitors VEOZAH is a substrate of CYP1A2. Concomitant use of VEOZAH with drugs that are weak, moderate, or strong CYP1A2 inhibitors, increase the plasma C max and AUC of VEOZAH. VEOZAH is contraindicated in individuals using CYP1A2 inhibitors.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Fezolinetant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Veozah 45 mg tabletOral | Astellas Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Fezolinetant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Fezolinetant, including Veozah.
Yes. The US FDA first approved Fezolinetant on 12 May 2023, according to Drugs@FDA.
Yes. Fezolinetant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Fezolinetant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Fezolinetant is classified under ATC code G02CX06 (Fezolinetant).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.